Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Cites Clinical Investigator In Six Trials Of Three Cystic Fibrosis Drugs

Executive Summary

FDA's oversight of clinical trials is becoming an increasingly significant factor in regulatory delays for some products, and a recent warning letter could have a very broad impact: it cites a clinical investigator for six trials related to three separate NDAs

You may also be interested in...

Cystic Fibrosis Trial Endpoints May Be Revised Following FDA Workshop

Quality-of-life metrics deserve consideration in addition to lung function in the development of aerosolized antimicrobials, researchers say.

Venture Philanthropists Say "Welcome To The Table" At Partnering Conference

Venture philanthropists have clearly been expanding their role in funding drug development beyond the basic research phase. Now, they want to collaborate more aggressively with traditional biopharma deal-makers, and an ambitious conference, FasterCures, recently organized in New York, took a step toward that goal. The organizers created a meeting based on a mixed format, which was comfortable for its diverse attendees - patient advocates, academics, and investors - yet drove the message: let's get something done

This Little Pig-Free Product Goes To Market? Alnara's High Hopes For A PERT

Alnara claims its latest trial shows real-world effectiveness of liprotamase, formerly called Trizytek, and plans early 2010 NDA.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts